PAPP-A2 Protein: A Key Metalloproteinase in IGF-1 Bioavailability Regulation and Growth Development

Author: Senior Product Manager of UA Views：5

This article focuses on the molecular characteristics and biological functions of pregnancy-associated plasma protein-A2 (PAPP-A2), systematically elaborating its molecular mechanism as a secreted metalloproteinase of the pappalysin family that hydrolyzes IGFBP-3/5 to release free IGF-1, analyzing its core regulatory roles in placental development, postnatal linear growth, and bone metabolism, and exploring the clinical phenotypes of deficiency syndrome caused by PAPP-A2 gene mutations as well as the interventional value of recombinant IGF-1 replacement therapy.

Recent Advances
Product Information

Recent Advances

PAPP-A2 Protein: A Key Metalloproteinase in IGF-1 Bioavailability Regulation and Growth and Development

Brief Introduction: This article focuses on the molecular characteristics and biological functions of pregnancy-associated plasma protein-A2 (PAPP-A2), systematically elaborating the molecular mechanism by which it, as a secreted metalloproteinase of the pappalysin family, hydrolyzes IGFBP-3/5 to release free IGF-1, analyzing its core regulatory role in placental development, postnatal linear growth, and bone metabolism, and discussing the clinical phenotype of PAPP-A2 deficiency syndrome caused by PAPP-A2 gene mutations as well as the interventional value of recombinant IGF-1 replacement therapy.

I. Molecular Characteristics and Family Assignment of PAPP-A2.

PAPP-A2 (pregnancy-associated plasma protein-A2) is a secreted metalloproteinase belonging to the pappalysin family. Its structure contains multiple functional domains and specifically hydrolyzes insulin-like growth factor binding protein 3 and 5. From the perspective of molecular structure, the catalytic domain of PAPP-A2 contains a typical zinc-dependent metalloproteinase motif, and its substrate specificity is determined by the interaction between non-catalytic domains and IGFBPs. PAPP-A2 is released into the extracellular space in a secreted form and exerts regulatory functions in the extracellular environment through proteolytic hydrolysis. This mode of action enables it to rapidly respond to changes in physiological demands and locally regulate the accessibility of growth factor signals. As a member of the pappalysin family that is structurally related to PAPP-A (pregnancy-associated plasma protein-A) but has different substrate preferences, PAPP-A2 has a unique position in the regulation of the IGF axis.

II. Molecular Mechanism by Which PAPP-A2 Regulates IGF-1 Bioavailability.

By cleaving IGFBPs, PAPP-A2 releases free IGF-1, thereby precisely regulating the bioavailability of IGF-1. Under physiological conditions, the vast majority of IGF-1 forms complexes with binding proteins such as IGFBP-3 and exists in the circulation in an inactive or low-activity form. This binding prolongs the half-life of IGF-1 but limits its binding to receptors. PAPP-A2 specifically hydrolyzes IGFBP-3 and IGFBP-5, breaking this binding equilibrium and releasing biologically active free IGF-1, enabling it to bind to IGF-1 receptors on the surface of target cells and activate downstream signaling pathways. This "cleavage-release" mechanism constitutes a key step in the regulation of IGF-1 bioavailability, making PAPP-A2 an important regulatory node connecting the growth hormone axis with local tissue growth demands.

III. Core Roles of PAPP-A2 in Placental Development, Linear Growth, and Bone Metabolism.

PAPP-A2 plays core roles in placental development, postnatal linear growth, and bone metabolism. In placental development, PAPP-A2 promotes trophoblast proliferation and invasion by releasing free IGF-1, participating in placental vascular formation and the establishment of the maternal-fetal interface. In postnatal linear growth, PAPP-A2-mediated IGF-1 release is an important driving factor for chondrocyte proliferation and hypertrophy in the growth plate of long bones. In bone metabolism, PAPP-A2 affects the functional balance of osteoblasts and osteoclasts by regulating the local availability of IGF-1. These different physiological processes collectively point to the core position of PAPP-A2 as a key regulatory factor in growth and development.

IV. Clinical Phenotype and Therapeutic Intervention of PAPP-A2 Deficiency Syndrome.

Clinical studies have shown that PAPP-A2 gene mutations lead to PAPP-A2 deficiency syndrome, characterized by idiopathic short stature, delayed bone age, and a unique biochemical phenotype of decreased free IGF-1 and elevated total IGF-1. This biochemical phenotype has high diagnostic suggestive value——elevated total IGF-1 reflects the accumulation of IGF-1 bound by IGFBPs, while decreased free IGF-1 directly reflects the impairment of biologically active IGF-1 release caused by the loss of PAPP-A2 hydrolytic function. Recombinant human IGF-1 replacement therapy can significantly improve patient growth. This therapeutic response further verifies that the pathological mechanism of PAPP-A2 deficiency syndrome lies in insufficient free IGF-1, and also provides an effective means for precise treatment of the disease.

V. Association Between PAPP-A2 and Preeclampsia and Its Biomarker Value.

In addition, abnormal placental expression of PAPP-A2 is closely associated with preeclampsia, indicating that it is not only a key regulatory factor in growth and development but also a potential biomarker for pregnancy complications. Preeclampsia is a serious complication of pregnancy, and its pathological mechanism involves placental ischemia and hypoxia as well as vascular endothelial dysfunction. Abnormal expression of PAPP-A2 in the placenta may participate in the occurrence and development of preeclampsia by affecting local IGF-1 bioavailability. As a potential biomarker, detection of PAPP-A2 may contribute to the early identification and risk stratification of preeclampsia, providing additional clinical information for pregnancy management.

VI. Conclusion.

In basic research and clinical translation exploration related to PAPP-A2, high-quality recombinant PAPP-A2 protein is a core tool for analyzing its substrate cleavage specificity and evaluating its biological functions. The His tag facilitates purification by immobilized metal affinity chromatography and enables detection and capture by anti-His tag antibodies. In response to the needs of PAPP-A2 functional research and exploration of growth and development regulatory mechanisms, U-AI provides PAPP-A2 His Tag Protein, Human. This product is suitable for applications such as analysis of PAPP-A2 cleavage activity on IGFBP-3/IGFBP-5, research on PAPP-A2-mediated free IGF-1 release mechanisms, functional research related to PAPP-A2 deficiency syndrome, and development of biomarkers for preeclampsia.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Nanjing Univ is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UNIV Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next